CITIC Securities: Innovation in nuclear medicine RDC changes the paradigm of diagnosing and treating prostate cancer, opening up a new blue ocean market worth billions.

Guotai Junan Securities research report indicates that the innovative nuclear medicine RDC is expected to address the unmet clinical needs in the current diagnosis and treatment process of prostate cancer, such as the high burden of testing and limited efficacy, change the paradigm of diagnosis and treatment of prostate cancer, achieve integration of diagnosis and treatment, improve patient compliance and survival. Currently, there is no RDC listed in China, the market is in a blue ocean state. Overseas prostate cancer RDC diagnostic and therapeutic products will be launched in 2021, and the market will reach nearly 3 billion US dollars by 2024, fully verifying its huge commercial value. We believe that China is expected to replicate the development path of the overseas prostate cancer RDC diagnostic and therapeutic market. It is estimated that the future Chinese prostate cancer RDC diagnostic and therapeutic market will exceed 10 billion yuan, and the market will show high-speed growth. We believe that the key points in this industry are isotopes, ligand molecular forms, and production and distribution capabilities, and recommend focusing on companies that have advantages in the above conditions.